Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
01
Overview
N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide is an experimental small molecule dipeptide composed of two phenylalanine residues, one of which is substituted with a difluorophosphonomethyl group. It belongs to the class of organic compounds known as dipeptides and has not been approved for any therapeutic use. There are no reported clinical trials or approved indications for this compound, and its mechanism of action remains uncharacterized in the literature[1][2]. The compound has been studied primarily in the context of synthetic chemistry and fluorinated amino acid research[3].
- Other names
- DB07651DB-07651DB 07651
Beyond the preview
Go deeper on N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide.